Cardiff Oncology (NASDAQ:CRDF – Get Rating) had its price objective increased by HC Wainwright from $14.00 to $15.00 in a research report report published on Tuesday morning, The Fly reports.
Cardiff Oncology Trading Up 7.6 %
Shares of CRDF stock opened at $1.85 on Tuesday. The company has a market cap of $82.66 million, a price-to-earnings ratio of -2.08 and a beta of 1.73. The stock has a 50 day simple moving average of $1.70 and a 200-day simple moving average of $1.69. Cardiff Oncology has a 12-month low of $1.13 and a 12-month high of $3.41.
Cardiff Oncology (NASDAQ:CRDF – Get Rating) last issued its earnings results on Thursday, March 2nd. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.05. The business had revenue of $0.13 million during the quarter, compared to the consensus estimate of $0.08 million. Cardiff Oncology had a negative return on equity of 32.95% and a negative net margin of 10,033.16%. On average, equities analysts forecast that Cardiff Oncology will post -1.12 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Cardiff Oncology
Cardiff Oncology Company Profile
Cardiff Oncology, Inc is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. It is focused on developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics.
- Get a free copy of the StockNews.com research report on Cardiff Oncology (CRDF)
- Under-the-Radar Azul SA Takes Flight on Robust Travel Demand
- Market Gets “Powelled”: S&P 500 Confirms Resistance
- Rivian Plummets, But Is This 2023’s Greatest Buying Opportunity?
- Ulta Insiders Hold Tight: Sell-Siders Buy
- Potential Earnings Have Rated Ambrx Biopharma a Moderate Buy
Receive News & Ratings for Cardiff Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiff Oncology and related companies with MarketBeat.com's FREE daily email newsletter.